Literature DB >> 8696949

Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits.

S Ameli1, A Hultgårdh-Nilsson, J Regnström, F Calara, J Yano, B Cercek, P K Shah, J Nilsson.   

Abstract

Although the existence of an immune response against modified lipoproteins in atherosclerosis has been observed in experimental animals as well as in humans, the precise pathophysiological relevance of these findings remains unclear. In this study we determined the effect of an immunization with homologous LDL and copper-oxidized LDL on the formation of atherosclerotic plaque in hypercholesterolemic rabbits. Immunizations were performed at the start of a cholesterol-rich diet and 3 weeks later. After 16 weeks, antibodies against oxidized LDL had developed in rabbits given hypercholesterolemic diet alone, but the titers were increased by twofold in rabbits immunized with oxidized LDL as well as in rabbits immunized with LDL, suggesting that the LDL had also become oxidized during the preparation and/or immunization procedure. Immunization with LDL and oxidized LDL reduced atherosclerotic lesions in the proximal aorta by 74% (P < .05) and 48% (P = NS), respectively. The cellular composition of the lesions was not affected by the immunizations. These results support the hypothesis that an immune response against modified LDL has a protective effect against the development of early atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8696949     DOI: 10.1161/01.atv.16.8.1074

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  69 in total

1.  Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.

Authors:  Hang Pong Ng; Ramona L Burris; Shanmugam Nagarajan
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

2.  Modulating atherothrombosis: is there a place for vaccines in global prevention strategies?

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 3.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 4.  Vaccines for cholesterol management.

Authors:  Charles W Rittershaus
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 5.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 6.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

7.  Mildly oxidized low-density lipoproteins suppress the proliferation of activated CD4+ T-lymphocytes and their interleukin 2 receptor expression in vitro.

Authors:  S Caspar-Bauguil; M Saadawi; A Negre-Salvayre; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 8.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

9.  Food restriction and fish oil suppress atherogenic risk factors in lupus-prone (NZB x NZW) F1 mice.

Authors:  Alagarraju Muthukumar; Khaliquz Zaman; Richard Lawrence; Jeffery L Barnes; Gabriel Fernandes
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

10.  Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.

Authors:  Aldar S Bourinbaiar; Vichai Jirathitikal
Journal:  Lipids Health Dis       Date:  2010-02-02       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.